Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05267470
Title A Study of Bemarituzumab Monotherapy and Docetaxel Combination in Participants With Squamous Non-small-cell Lung Cancer (SqNSCLC) With Fibroblast Growth Factor Receptor Isoform 2b (FGFR2b) Overexpression (FORTITUDE-201)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Amgen
Indications

lung squamous cell carcinoma

Therapies

Bemarituzumab

Bemarituzumab + Docetaxel

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | BEL


No variant requirements are available.